Who
Bernd R. Seizinger
Other role
Company insider
Files Form 4 as: Director and Other, Aptose Biosciences; Director, Aprea Therapeutics; Director, Oncolytics Biotech.
In numbers
- Trades disclosed
- 44
- Buys
- 9
- Sells
- 0
- Bought
- $578K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 7 Oct 2019
- Last trade
- 30 Jun 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 2 Jul 2026 | Aptose BiosciencesBiotechnology | SEC FORM 4 Code D | $29K17,000 at $1.72 | filing |
| 30 Jun 2026filed 2 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —3,333 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —100,000 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —3,333 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —100,000 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | Aptose Biosciences | SEC FORM 4 Code D | $29K17,000 at $1.72 | filing |
| 16 Jun 2026filed 17 Jun 2026 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,135 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,555 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,555 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,135 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ONCY Oncolytics Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ONCY Oncolytics Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ONCY Oncolytics BiotechBiotechnology | SEC FORM 4 Bought | $34K40,000 at $0.8466 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ONCY Oncolytics BiotechBiotechnology | SEC FORM 4 Bought | $34K40,000 at $0.85 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ONCY Oncolytics BiotechBiotechnology | SEC FORM 4 Bought | $50K60,000 at $0.8265 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ONCY Oncolytics BiotechBiotechnology | SEC FORM 4 Bought | $50K60,000 at $0.83 | filing |
| 16 Jan 2026filed 20 Jan 2026 | ONCY Oncolytics BiotechBiotechnology | SEC FORM 4 Bought | $104K100,000 at $1.04 | filing |
| 16 Jan 2026filed 20 Jan 2026 | ONCY Oncolytics BiotechBiotechnology | SEC FORM 4 Bought | $104K100,000 at $1.04 | filing |
News
Oncolytics Biotech (NASDAQ:ONCY) Stock Price Up 9.8% – Still a Buy?ONCY · dailypolitical.com · 16 Oct 2026Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant PaymentONCY · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Bernd R. Seizinger; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.